Shares of Twist Bioscience Corp (TWST) plunged 12.16% in Monday's pre-market session, despite the company reporting better-than-expected fiscal Q1 2025 results. The synthetic DNA manufacturer's stock suffered a sharp sell-off as investors expressed concerns over the company's forward guidance.

For the first quarter ended December 2024, Twist Bioscience reported revenue of $88.7 million, surpassing Wall Street expectations of $86.9 million. The company also posted a narrower loss of $0.53 per share, beating analysts' estimates of a $0.62 per share loss.

However, Twist Bioscience's outlook failed to impress investors. The company projected Q2 2025 revenue in the range of $91 million to $93 million, while full-year 2025 revenue is expected to be between $372 million and $379 million. These forecasts seemingly fell short of market expectations, triggering a sell-off in TWST's shares.